Bayer appoints new head of pharma business development & licensing
Bayer has bolstered its pharma division, appointing Marianne De Backer (pictured below) as its new head of business development & licensing. She is also set to join the company’s pharmaceuticals executive committee with immediate effect.
De Backer will be based in Berkeley, California and will lead Bayer’s external pharmaceutical growth strategy and activities globally. She joins Bayer from Johnson & Johnson, where she held senior roles and led business development activities across a variety of therapeutic areas and locations. Most recently, she held the position of vice president of M&A operations and divestitures and led the infectious diseases and vaccines business development.
“Marianne De Backer is a recognised business leader with an impressive track record spanning over two decades in research and commercial, as well as licensing, mergers and acquisitions,” said Stefan Oelrich, member of the board of management, Bayer.
“Her breadth of experience in successfully forming and managing external alliances will be one of the key drivers for Bayer’s continued growth, ultimately aimed at providing new medicines and solutions to patients,” he added.
Priya Chaturvedi joins Eisai
Eisai Inc, the US pharma subsidiary of Eisai Co, has appointed Priya Chaturvedi (pictured below) as vice president of global clinical quality assurance.
Chaturvedi will be responsible for developing, implementing and monitoring global policies and procedures, to assure the worldwide compliance with good clinical practices and the laws and regulations governing drug development.
She joins Eisai from Merck, where she served as executive director, clinical quality assurance, head of global GCP for infectious disease and vaccines. In that role, Chaturvedi oversaw the end-to-end quality assurance for a large portfolio of clinical trials across all therapeutic areas in the Asia-Pacific region, including China. Prior to this, she held roles at Pfizer and GlaxoSmithKline.
Accord Healthcare names new head of scientific affairs
Anthony Grosso (pictured below) has been appointed to the role of head of scientific affairs at Accord Healthcare Europe. Grosso will be responsible for overseeing Accord’s ongoing strategy for medicine development.
Prior to joining Accord, Grosso held a number of senior public and commercial roles, including the role of principal medicines management pharmacist at UCL Hospitals. Grosso is also a registered pharmacist, and has a long-standing interest in the efficient use of medicines.
“We are thrilled to have Anthony join our senior team,” said James Burt, executive vice president, Europe and MENA at Accord.
“Anthony’s experience in running pharmaceutical businesses and his time at the coal-face of pharmacy delivery will help us achieve these goals and adds to our burgeoning team of generics and biosimilar specialists,” he added.